<DOC>
	<DOCNO>NCT00603252</DOCNO>
	<brief_summary>This protocol post describes booster phase study . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00289731 ) .</brief_summary>
	<brief_title>Study Show That Combined Hepatitis A B Vaccine Non-inferior Monovalent Vaccines Adults</brief_title>
	<detailed_description>All subject receive dose vaccine receive primary study ( 100382 ) , approximately 4 year first dose . Blood sample take administration vaccine dose evaluate anti-HAV anti-HBs antibody response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female complete primary vaccination phase study . Written inform consent obtain subject . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . History hepatitis A hepatitis B vaccination infection , since primary vaccination study . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>combine hepatitis A B vaccine</keyword>
	<keyword>risk factor</keyword>
</DOC>